Monographie - Verapamil hydrochloride

Dernière mise à jour :
19/11/2024

Verapamil hydrochloride

Structure chimique

Noms commerciaux

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Calaptin	Inde
Calovera	Inde
Cordilox	Grande Bretagne
Dilacoran	Mexique
Filacard	Allemagne
Flamon	Suisse
Geangin	Danemark
Isocor	Roumanie
Isoptin	Allemagne, Arabie Saoudite, Australie, Autriche, Egypte, Etats Unis d’Amérique, Grèce, Italie, Nouvelle Zélande, Pays bas, Pologne, Portugal, Suède, Suisse
Isoptina	Chili
Isoptine	Belgique, France, Luxembourg
Izoptomil	Egypte
Lekoptin	Iran
Manidon	Espagne
Palyuan	Mexique
Securon	Grande Bretagne
Serriten	Mexique
Unimylo	Mexique
Vasolan	Japon
Verahexal	Allemagne
Veraloc	Danemark
Veramex	Allemagne
Verapabene	Autriche
Verapam	Suisse
Verapamil	Allemagne, Canada, Etats Unis d’Amérique, Hongrie, Suède
Verapamilo	Argentine, Chili, Colombie, Equateur, Pérou
Verpamil	Finlande, Malaisie

Bibliographie : Verapamil hydrochloride

	Type	Source
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
191	Revue	Riley CM. Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1988 ; 45: 2079-2091.
242	Revue	Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M. Stability of amiodarone hydrochloride in admixtures with other injectable drugs. Am J Hosp Pharm 1986 ; 43: 917-921.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
364	Revue	Johnson CE, Lloyd CW, Mesaros JL, Rubley GJ. Compatibility of aminophylline and verapamil in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 97-100.
371	Revue	Thompson DF, Stiles ML, Allen LV, Tu YH. Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 142-145.
372	Revue	Johnson CE, Lloyd CW, Aviles AI, Rybarz KL. Compatibility of premixed theophylline and verapamil intravenous admixtures. Am J Hosp Pharm 1988 ; 45: 609-612.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
706	Revue	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1045	Revue	Das Gupta V, Stewart KR. Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5 % dextrose injections. Am J Hosp Pharm 1984 ; 41: 686-689.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1098	Revue	Cutie MR. Verapamil precipitation. Ann Intern Med 1983 ; 98: 672.
1099	Revue	Tucker R, Gentile JF. Precipitation of verapamil in an intravenous line. Ann Intern Med 1984 ; 101: 880.
1100	Revue	Bar-Or D, Kulig K, Marx JA, Rosen P. Precipitation of verapamil. Ann Intern Med 1982 ; 97: 619.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1351	Revue	Tucker R, Gentle JF. Precipitation of verapamil with nafcillin. Am J Hosp Pharm 1984 ; 41: 2588.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1944	Revue	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1964	Revue	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
2018	Revue	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2328	Laboratoire	Sugammadex (Bridion®) – Résumé des caractéristiques du produits Organon 2009
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3934	Laboratoire	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
4130	Revue	Koller AK, Krebs S, Dörje F. Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzen Arzneimittel auf Intensivstationen. Pharmaceutics 2021 , 13, 21.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales